MERCK KGAA

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1668-01-01

Employees: 62.9K

Market Cap: $84.2B

Website: http://www.merckgroup.com/de

Clinical Trials

A Phase IV, Prospective, Observational, Open Label, Single Centre Cohort Trial to be Conducted in Norway During One Year to Assess the Cumulative Pregnancy Rate in a New Series of In-vitro Fertilization (IVF) Treatment Cycles Following Three or More Previous IVF Treatment Cycles Without Live Birth

Completed

Conditions: Infertility

First Posted Date: 2010-02-19

Last Posted Date: 2014-05-05

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 166

Registration Number: NCT01071148

Locations: 🇳🇴
Klinikk Hausken, Haugesund, Norway

A Trial to Evaluate the Correlation Between Spontaneous Catch-up Growth, Clinical Response to Saizen (Recombinant Human Growth Hormone, r-hGH) and Gene Expression Profiling in Children Small for Gestational Age (SGA)

Phase 3

Terminated

Conditions: Infant, Small for Gestational Age

Interventions: Drug: Recombinant human growth hormone (r-hGH)

First Posted Date: 2010-02-11

Last Posted Date: 2013-12-27

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 25

Registration Number: NCT01067352

Locations: 🇮🇹
Merck Serono S.p.A., Roma, Italy

Phase 4 Study to Assess the Effect of Bisoprolol on Glycemic Level in Type II Diabetic Subjects With Suboptimal Blood Pressure Control

Phase 4

Completed

Conditions: Hypertension
Diabetes Mellitus, Type II

Interventions: Drug: Bisoprolol

First Posted Date: 2010-02-10

Last Posted Date: 2014-07-04

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 202

Registration Number: NCT01066039

Locations: 🇰🇷
Seoul St. Mary´s Hospital, Seoul, Korea, Republic of

Sprifermin (AS902330) in Cartilage Injury Repair (CIR)

Phase 2

Terminated

Conditions: Isolated Cartilage Injury of the Knee

Interventions: Drug: Sprifermin (AS902330) 30 mcg
Other: Placebo
Drug: Sprifermin (AS902330) 10 mcg
Drug: Sprifermin (AS902330) 100 mcg

First Posted Date: 2010-02-10

Last Posted Date: 2016-03-23

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 74

Registration Number: NCT01066871

Locations: 🇩🇪
Please contact the Merck KGaA Communication Center, Darmstadt, Germany

Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years

Phase 4

Completed

Conditions: Turner's Syndrome

Interventions: Drug: r-hGH

First Posted Date: 2010-02-10

Last Posted Date: 2018-12-14

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 115

Registration Number: NCT01066052

Locations: 🇫🇷
Hôpital Robert Debré, Paris, France

Comparative Validation of the Growth Hormone Releasing Hormone and Arginine Test for the Diagnosis of Adult Growth Hormone Deficiency

Phase 3

Completed

Conditions: Growth Hormone Deficiency

Interventions: Other: ITT, ITT, GHRH+Arg.
Other: GHRH+Arg, GHRH+Arg, ITT

First Posted Date: 2010-02-02

Last Posted Date: 2014-08-05

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 69

Registration Number: NCT01060488

Locations: 🇫🇷
CHU Bicêtre, Endocrinology and Reproductive Diseases Department, Le Kremlin Bicêtre, France

A Multicenter Study of rhFGF 18 in Patients With Knee Osteoarthritis Not Requiring Surgery

Phase 1

Completed

Conditions: Knee Osteoarthritis

Interventions: Biological: AS902330

First Posted Date: 2009-12-17

Last Posted Date: 2014-06-25

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 192

Registration Number: NCT01033994

Locations: 🇨🇦
SKDS Research, Inc., Newmarket, Canada
🇫🇮
Oulu University Hospital, Surgical and Intensive Care Division, Oulu, Finland
🇨🇦
Kells Medical Research Group, Pointe Claire, Canada

and more 25 locations

Pharmacogenetic Trial and Long-term Follow-up of the PRISMS Trial (PRISMS-15)

Completed

Conditions: Multiple Sclerosis

First Posted Date: 2009-12-17

Last Posted Date: 2014-07-31

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 290

Registration Number: NCT01034644

Locations: 🇨🇭
Please call/email Central Contact for Recruiting Information in, Geneva, Switzerland

EMD 521873 in Advanced Solid Tumors, MTD Finding

Phase 1

Completed

Conditions: Non-Hodgkin Lymphoma

Interventions: Biological: EMD 521873

First Posted Date: 2009-12-15

Last Posted Date: 2014-07-31

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 66

Registration Number: NCT01032681

Locations: 🇨🇭
University of Lausanne Hospitals (CHUV) and Hospitals of Riveria-Chablais, Lausanne, Switzerland
🇨🇭
Kantonsspital St. Gallen, St.Gallen, Switzerland
🇩🇪
Medizinische Klinik Universitätsklinikum Mannheim Medizinische Fakultät Mannheim, Mannheim, Germany

and more 2 locations

Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population

Phase 3

Terminated

Conditions: Non-Small Cell Lung Cancer

Interventions: Biological: Tecemotide
Drug: Placebo
Drug: Single low dose cyclophosphamide
Other: Saline
Other: Best Supportive Care (BSC)

First Posted Date: 2009-11-18

Last Posted Date: 2016-10-26

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 285

Registration Number: NCT01015443

Locations: 🇨🇳
Chang Gung Medical Foundation, Kaohsiung, Kaohsiung County, Taiwan
🇨🇳
China Medical University Hospital, Taichung City, Taiwan
🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan

and more 44 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy